IMUNON, Inc. announced on April 21, 2025, that an abstract highlighting new, encouraging Overall Survival data from its Phase 2 OVATION 2 Study of IMNN-001 was accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting is scheduled for May 30 - June 3, 2025, in Chicago, Illinois.
This recognition underscores the significant potential of IMNN-001 to transform the treatment of women with newly diagnosed advanced ovarian cancer, a population that has not seen treatment innovation in over 25 years. IMNN-001 is the first and only IL-12 immunotherapy to achieve a clinically effective response, including overall survival benefit, in frontline treatment for advanced ovarian cancer.
The company recently announced alignment with the U.S. Food and Drug Administration (FDA) on the study protocol for the Phase 3 OVATION 3 clinical trial of IMNN-001 and has initiated trial site activation. The upcoming ASCO presentation will further disseminate these important clinical findings to the global oncology community.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.